OpenAI has invested in Red Queen Bio, an AI biosecurity company focused on developing defenses against AI-enabled biological threats. This investment is part of a $15 million seed funding round, with OpenAI as the lead investor. The startup's mission is to scale biological defenses at a faster rate than the advancement of frontier AI capabilities, particularly in the context of bioweapons.
Red Queen Bio, co-founded by Hannu Rajaniemi and Nikolai Eroshenko, emerged from their previous work at HelixNano, an mRNA company. During a collaboration with OpenAI, they observed the significant biological creativity of frontier AI models, which inspired them to build defensive infrastructure against potential misuse. The company aims to map AI-enabled biothreats and create medical countermeasures, such as new drugs, by leveraging leading AI models, lab automation, and reinforcement learning. This approach, combined with on-demand biologics manufacturing, is designed to enable defensive co-scaling with AI advancements.
The startup's strategy involves a two-layer system: diversity generation and target identification. The first layer focuses on generating diverse antibody variants using AI, aiming for zero-shot design ability against various pathogens. The second layer involves AI models that can analyze novel pathogen sequences, identify critical epitopes, and direct antibody design. While Red Queen Bio is a public benefit corporation, it also explores commercial applications for its antibody design platform in areas like autoimmune disease and oncology, viewing these as capability-building exercises. The company has partnered with AbTherx to combine AbTherx’s Atlas Full Human Diversity Transgenic Mouse platform with Red Queen Bio’s AI-driven antibody development for therapeutic antibody discovery.
Red Queen Bio emphasizes that it does not conduct dangerous gain-of-function research or create dangerous pathogens. Their work is designed to ensure that scientific advancements in AI biology primarily lead to new treatments and cures, rather than enabling harmful applications. The investment from OpenAI highlights the growing concern within the AI industry about the potential risks posed by advanced AI and the need for proactive defensive measures.
